Questcor Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference
ANAHEIM, Calif., March 9, 2011 /PRNewswire/ — Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) announced today that executive management will present at the Barclays Capital Global Healthcare Conference to be held March 15-17, 2011 at the Loews Miami Hotel in Miami, Florida. Don M. Bailey, President and Chief Executive Officer, is scheduled to present an overview of the Company on Wednesday, March 16, 2011 at 2:30 p.m. ET.
To listen to the audio web cast of the presentation during or after the event, please visit: www.questcor.com. The replay will be available for ninety days after the event.
Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions. Questcor’s primary product is H.P. ActharÃ‚® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from two indications: the treatment of acute exacerbations of multiple sclerosis in adults and the treatment of infantile spasms in children under two years of age. Questcor is also implementing plans to commercialize Acthar for use in treating nephrotic syndrome, another on-label indication. Specifically with respect to nephrotic syndrome, the FDA has approved Acthar to “induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus.” Questcor also markets Doral(R) (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.
SOURCE Questcor Pharmaceuticals, Inc.